Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13148-016-0197-2 http://scihub22266oqcxt.onion/10.1186/s13148-016-0197-2 C4789293!4789293 !26973719     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26973719 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Clin+Epigenetics 2016 ; 8 (?): 31 Nephropedia Template TP {{tp|p=26973719 |t=2016. 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |pdf=|usr=}}{{26973719 }} gab.com Text 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma JO: Clin Epigenetics http://www.kidney.de/pget.php?&tw=1&pmid=26973719 #FOAvip BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80-85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1-5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p?<?0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels. A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of 5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth. CONCLUSIONS: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth regulatory role of TET1 in parathyroid tissue. Twit Text FOAVip 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma ????Clin Epigenetics http://www.kidney.de/pget.php?&tw=1&pmid=26973719 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26973719 #FOAvip English Wikipedia <ref>{{Cite pmid|26973719 }}</ref> 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma #MMPMID26973719 Barazeghi E ; Gill AJ ; Sidhu S ; Norlén O ; Dina R ; Palazzo FF ; Hellman P ; Stålberg P ; Westin G Clin Epigenetics 2016[]; 8 (?): 31 PMID26973719 show ga BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80-85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1-5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p? |5-Methylcytosine/analogs & derivatives [MESH] |Adenoma/*chemistry/enzymology [MESH] |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Blotting, Western [MESH] |Case-Control Studies [MESH] |Cytosine/*analogs & derivatives/analysis [MESH] |DNA-Binding Proteins/metabolism [MESH] |Humans [MESH] |Middle Aged [MESH] |Mixed Function Oxygenases [MESH] |Parathyroid Glands/chemistry/enzymology [MESH] |Parathyroid Neoplasms/*chemistry/enzymology [MESH] |Proto-Oncogene Proteins/metabolism [MESH] |Real-Time Polymerase Chain Reaction [MESH]5-Hydroxymethylcytosine discriminates between parathyroid adenoma and (epmc).pdf DeepDyve Pubget Overpricing